Pharma Mar SA 2024 SR
The report highlights Pharma Mar's commitment to oncology research using marine-derived compounds, achieving a 39.2% reduction in Scope 1 and 2 emissions compared to the 2021 base year. Key milestones include the inauguration of the Sylentis laboratory with photovoltaic capacity and the establishment of a Net Zero Plan validated by SBTi. The company also implemented a Human Rights Policy and conducted a double materiality assessment aligned with ESRS. Socially, women represent 60.6% of the workforce, and the company maintains 100% permanent contracts.
Company: Pharma Mar SA
Sector: Health Care
Country: Spain
Year: 2024
Type: SR
Pages: 140
Pharma Mar SA
Consolidated Non-Financial Information Statement And Sustainability Information
The report highlights Pharma Mar's commitment to oncology research using marine-derived compounds, achieving a 39.2% reduction in Scope 1 and 2 emissions compared to the 2021 base year. Key milestones include the inauguration of the Sylentis laboratory with photovoltaic capacity and the establishment of a Net Zero Plan validated by SBTi. The company also implemented a Human Rights Policy and conducted a double materiality assessment aligned with ESRS. Socially, women represent 60.6% of the workforce, and the company maintains 100% permanent contracts.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Feb 27, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees